Utilization of Home-Based Medical Services by Clinicians for Medicaid Recipients
Overview
This study examines the utilization of home-based medical care (HBMC) for non-dual eligible Medicaid beneficiaries from 2018 to 2022. It highlights an increase in both the number of clinicians providing HBMC and the number of beneficiaries receiving these services, particularly among advanced practice registered nurses (APRNs).
Background
Home-based medical care (HBMC) is increasingly recognized for its potential to reduce emergency department visits and hospitalizations while enhancing patient satisfaction, particularly for Medicaid beneficiaries. With approximately 80 million individuals covered by Medicaid, understanding the workforce and utilization trends in HBMC is crucial for improving care delivery. The COVID-19 pandemic has influenced the landscape of healthcare delivery, making it important to analyze changes in HBMC utilization during this period.
Data Highlights
Year
Clinicians Providing HBMC
Beneficiaries Receiving HBMC
HBMC Rate per 1000 Beneficiaries
2018
6063
59876
1.4
2022
8033
75922
1.6
Key Findings
In 2018, 6063 clinicians provided HBMC to non-dual eligible Medicaid beneficiaries, increasing to 8033 by 2022.
APRNs accounted for 62% of HBMC visits in 2022, up from 48.7% in 2018.
The number of beneficiaries receiving HBMC increased by 26.8% from 2018 to 2022.
Beneficiaries with disabilities represented the largest group receiving HBMC, though their proportion decreased from 49.9% to 45.1% during the study period.
The adjusted HBMC rate increased by 14.3% from 1.4 to 1.6 per 1000 beneficiaries.
Clinical Implications
The findings indicate a growing trend in the provision of HBMC services, particularly by APRNs.
Conclusion
The study reveals an increase in HBMC utilization among Medicaid beneficiaries, highlighting the evolving role of clinicians in delivering care in home settings.
National survey findings suggest many US adults report making health decisions based on social media despite widespread concerns about the accuracy of health information shared to the platforms.
The action relates to previously identified third-party manufacturing deficiencies rather than concerns about the clinical efficacy or safety data, according to the company.
